Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597906 | 0.94 | CCR5 (0.37) | CCR5MEN1KMT2APOLBPDE5A | |
| SCHEMBL3587526 | 0.87 | CCR5 (0.39) | CCR5MEN1KMT2APOLB | |
| SCHEMBL3598390 | 0.86 | PDE4A (0.41) | CCR5MEN1KMT2APOLBLMNA | |
| SCHEMBL3594810 | 0.86 | MEN1 (0.39) | CCR5MEN1KMT2APOLBLMNA | |
| SCHEMBL3593561 | 0.85 | CCR5 (0.37) | CCR5MEN1KMT2APOLBLMNA | |
| SCHEMBL3592312 | 0.85 | MAPT (0.37) | CCR5MEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL3600445 | 0.84 | CCR5 (0.38) | CCR5MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL3587745 | 0.84 | CCR5 (0.37) | CCR5MEN1KMT2APOLB | |
| SCHEMBL3588544 | 0.84 | CCR5 (0.37) | CCR5MEN1KMT2APOLB | |
| SCHEMBL3588547 | 0.84 | CCR5 (0.37) | CCR5MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | CCR5 958/4885MEN1 3628/4885KMT2A 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.